FDA considers approval of over-the-counter birth control pill in the US.

Two FDA panels are voting on whether to recommend the agency approve the country’s first non-prescription birth control pill, Opill, for over-the-counter sale. FDA career scientists have raised red flags about the drug’s safety and efficacy, even as the agency and the White House are under pressure to expand contraceptive options in a highly charged political environment around access to abortion. The FDA’s independent advisers met Tuesday and will meet Wednesday to review data from the pill’s maker to decide whether to recommend the FDA approve the drug.